New Facility Triples Production Capacity for Vaccine Related Equipment

Laboratory

Biotage has opened another building facility which means the manufacturing volume of equipment vital in the supply for making Covid- 19 vaccines has been able to triple.

Biotage is one of very few companies presenting off-the-shelf products for the purification of large-scale lipids, used in mRNA vaccine development and production. By increasing the quantity of large-scale flash columns by 300%, Biotage is aiding pharma firms and contract manufacturers’ in upscaling lipid manufacturing for Covid-19 vaccines.

“Biotage is one of very few companies presenting off-the-shelf products for the purification of large-scale lipids, used in mRNA vaccine development and production“

The lipids that were required for Lipid Nano Particles formulations used in the vaccines have not previously been accessible in the right capacity to globally manufacture billions of vaccine doses.

Anders Wikström, EVP Operations of Biotage, said “Our customers needed to manufacture their products on a significantly larger scale, and we were able to invest in an expansion of our existing production facilities to support their requirements. We were very pleased to be able to deliver this expansion in just over four months in order to meet the needs of present and potential new clients”

CEO and President of Biotage, Tomas Blomquist, said “This initiative is an example of how Biotage has a positive impact on society in line with our ethos HumanKind Unlimited. At the same time, it proves that we have a keen ear to our customers’ needs and have built an organization capable of moving quickly to meet new demand in rapidly growing niche markets within the pharmaceutical industry”

Return to news